Equity · Healthcare
CRNX
NASDAQCrinetics Pharmaceuticals (CRNX)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 9.0B USD
- Revenue, year to Dec 2025
- 7.7M USD
- EPS, diluted, year to Dec 2025
- −4.95 USD
- 52-week range
- 30 USD – 85 USD
- Avg volume
- 1.0M
as of Aug 31, 2026
Have Crinetics Pharmaceuticals (CRNX) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, no Crinetics Pharmaceuticals insider bought or sold shares on the open market; all 12 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Form 4, 90 days to 10 Nov 2026, newest Form 4 filing 1 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Sep 2026 | Bedrosian Camille LDirector | Other | 22,225 | 1.9M USD |
| 01 Sep 2026 | Betz Stephen F.Chief Scientific Officer | Other | 137,936 | 11.7M USD |
| 01 Sep 2026 | Struthers Richard ScottPresident & CEO | Other | 1,402,911 | 119.2M USD |
| 01 Sep 2026 | Schilke TobinChief Financial & Infra. Ofcr. | Other | 79,427 | 6.8M USD |
| 01 Sep 2026 | Kalofonos IsabelChief Commercial Officer | Other | 35,669 | 3.0M USD |
| 01 Sep 2026 | Deardorf CarenDirector | Other | 22,225 | 1.9M USD |
| 01 Sep 2026 | Fust Matthew KDirector | Other | 28,761 | 2.4M USD |
| 01 Sep 2026 | Nichols WestonDirector | Other | 22,225 | 1.9M USD |
| 01 Sep 2026 | Okey StephanieDirector | Other | 12,325 | 1.0M USD |
| 01 Sep 2026 | Vivaldi Coelho RogerioDirector | Other | 19,225 | 1.6M USD |
| 01 Sep 2026 | WIERENGA WENDELLDirector | Other | 122,071 | 10.4M USD |
| 20 Aug 2026 | Schilke TobinChief Financial & Infra. Ofcr. | Award | 471 |
Which funds hold Crinetics Pharmaceuticals (CRNX)?
0 of the 45 institutional funds we track reported a Crinetics Pharmaceuticals position for the quarter ended 30 Sep 2026; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Exited |
Have members of Congress traded Crinetics Pharmaceuticals (CRNX)?
The most recent congressional trade disclosed in Crinetics Pharmaceuticals is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 03 Mar 2026.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 03 Mar 2026 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 35 days |
| 17 Apr 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 19 days |
| 19 Mar 2025 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 22 days |
| 29 Jan 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 13 days |
| 25 Sep 2024 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 8 days |
What has been filed or recorded for Crinetics Pharmaceuticals (CRNX)?
The filings we hold for Crinetics Pharmaceuticals, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Jun 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −1.14 USD | |
| 30 Jun 2026 | Financials | Total assets | 1.3B USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 1.2B USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −1.23 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −4.95 USD | |
| 31 Dec 2025 | Financials | Revenue | 7.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −465.3M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −4.95 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −1.38 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −1.23 USD | Revenue $1M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −1.04 USD | Revenue $0M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −3.69 USD | Revenue $1M |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.96 USD |
What do people ask about Crinetics Pharmaceuticals (CRNX)?
What did Crinetics Pharmaceuticals shares close at?85.00
Crinetics Pharmaceuticals closed at 85.00 USD on 31 Aug 2026, up 0.18% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Crinetics Pharmaceuticals’ market cap?9.0B
Crinetics Pharmaceuticals is worth 9.0B USD by market value as of 31 Aug 2026, which is the share price times the shares on issue from its SEC filings.
What is Crinetics Pharmaceuticals’ revenue?7.7M
Crinetics Pharmaceuticals reported revenue of 7.7M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Crinetics Pharmaceuticals insiders bought or sold shares recently?12 filings
In the 90 days to 10 Nov 2026, no Crinetics Pharmaceuticals insider bought or sold shares on the open market; all 12 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders
Which funds own Crinetics Pharmaceuticals?0 of 45
0 of the 45 funds we track reported a Crinetics Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
Have members of Congress traded Crinetics Pharmaceuticals?5 trades
Yes. 5 trades in Crinetics Pharmaceuticals appear in the congressional disclosures we hold; the latest is a purchase by Gilbert Ray Cisneros, Jr. (House, CA) dated 3 Mar 2026, filed 7 Apr 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Crinetics Pharmaceuticals last report earnings?−1.14
Crinetics Pharmaceuticals last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −1.14 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Gilbert Ray Cisneros, Jr.: United States Department of Defense, Public domain; Josh Gottheimer: Kristie Boyd; U.S. House Office of Photography, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings